Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Resistant Prostate Cancer Patients”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchLooking for participantsNCT07798778
What this trial is testing

Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 18
Not applicableStudy completedNCT02236637
What this trial is testing

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

Who this might be right for
Prostate Cancer
Janssen Pharmaceutica N.V., Belgium 3,050
Testing effectiveness (Phase 2)Study completedNCT02598895
What this trial is testing

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
University of Washington 14
Testing effectiveness (Phase 2)Study completedNCT00337077
What this trial is testing

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Adenocarcinoma of the ProstateHormone-refractory Prostate CancerRecurrent Prostate Cancer+1 more
National Cancer Institute (NCI) 121
Not applicableUnknownNCT05078151
What this trial is testing

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Vall d'Hebron Institute of Oncology 69
Testing effectiveness (Phase 2)Study completedNCT00258388
What this trial is testing

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 82
Testing effectiveness (Phase 2)Study completedNCT01818986
What this trial is testing

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castrate-resistant Prostate CancermCRPC
University of Texas Southwestern Medical Center 20
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Early research (Phase 1)Temporarily pausedNCT05425862
What this trial is testing

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 48
Post-approval studies (Phase 4)Study completedNCT02721433
What this trial is testing

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Who this might be right for
Breast CancerProstate CancerMetastasis
Ottawa Hospital Research Institute 263
Testing effectiveness (Phase 2)Study completedNCT04862091
What this trial is testing

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd. 69
Testing effectiveness (Phase 2)Study completedNCT00394810
What this trial is testing

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
CASI pharmaceuticals, Inc. 21
Testing effectiveness (Phase 2)Ended earlyNCT01352208
What this trial is testing

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

Who this might be right for
Castrate Resistant Prostate Cancer
Astellas Pharma Inc 13
Testing effectiveness (Phase 2)Looking for participantsNCT06922318
What this trial is testing

The COSMYC Trial (COmbined Suppression of MYC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Not applicableStudy completedNCT01833208
What this trial is testing

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneRecurrent Prostate Carcinoma+1 more
Roswell Park Cancer Institute 15
Early research (Phase 1)Looking for participantsNCT07533708
What this trial is testing

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

Who this might be right for
mCRPC or Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech 48
Testing effectiveness (Phase 2)Study completedNCT01243385
What this trial is testing

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT02905318
What this trial is testing

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 19
Testing effectiveness (Phase 2)Looking for participantsNCT05168618
What this trial is testing

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
University of Utah 33
Large-scale testing (Phase 3)Not Yet RecruitingNCT07641855
What this trial is testing

BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 180
Next Page